Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition.
Jin W. · 2020
Read Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition. by Jin W. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7017057.txt.
Introduction
Jin reviews the JAK/STAT3 signalling pathway in the journal Cells, writing as sole author. When switched on, this pathway helps cancers grow, spread, and resist chemotherapy. Much of that effect runs through the epithelial-mesenchymal transition. That shift lets settled tumour cells become mobile and invasive.
The review explains how signals such as interleukin-6 turn the pathway on. It then traces how active STAT3 raises spread and helps form cancer stem cells. Those stem-like cells are blamed for many treatment failures. Jin also covers the tumour surroundings, the role of small RNAs called miRNAs, and new regulators of the pathway. The survey links basic signalling to the traits that make cancers hard to cure.
Catalog record
| CREATOR | Jin W. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 97 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial–Mesenchymal Transition By Wook Jin Published in: Cells DOI: 10.3390/cells9010217 ABSTRACT Abstract The JAK/STAT3 signaling pathway plays an essential role in various types of cancers. Activation of this pathway leads to increased tumorigenic and metastatic ability, the transition of cancer stem cells (CSCs), and chemoresistance in cancer via enhancing the epithelial–mesenchymal transition (EMT). EMT acts as a critical regulator in the progression of cancer and is involved in regulating invasion, spread, and survival. Furthermore, accumulating evidence indicates the failure of conventional therapies due to the acquisition of CSC properties. In this review, we summarize the effects of JAK/STAT3 activation on EMT and the generation of CSCs. Moreover, we discuss cutting-edge data on the link between EMT and CSCs in the tumor microenvironment that involves a previously unknown function of miRNAs, and also discuss new regulators of the JAK/STAT3 signaling pathway. Keywords: JAK/STAT, JAK/STAT, metastasis, the transition of cancer stem cells (CSCs), chemoresistance, epithelial–mesenchymal transition (EMT) 1. INTRODUCTION The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway played a crucial role in many biological functions during the multistep development of human tumors, including proliferation, inflammation, and survival. The JAK/STAT signaling pathway comprises of the receptor and adaptor proteins of interleukin 6 (IL-6), interferon-alpha (IFN-α), and interferon-gamma (IFN-γ) that mediate pleiotropic functions upon binding to their respective ligands [1,2]. The IL-6 family of cytokine comprises IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), cardiotrophin 1 (CT-1), ciliary neurotrophic factor (CNTF), cardiotrophin-like cytokine factor 1 (CLCF1), and leukemia inhibitory factor (LIF). Elevated expression of the cytokines belonging to this family is implicated in the development of various human diseases [3,4]. Upon binding IL-6, the IL-6 receptor-α (IL-6R) forms a complex with glycoprotein 130 (IL-6Rβ), and subsequently, triggers the activation of receptor-associated JAK1, JAK2, and tyrosine-protein kinase 2 (TYK2) pathways [4,5]. There are four JAK family non-receptor tyrosine kinases, JAK1, JAK2, JAK3, and TYK2. JAK1, JAK2, and TYK2 are ubiquitously expressed, whereas JAK3 is predominantly expressed in hematopoietic cells [6]. The JAK family is characterized by the presence of four unique domains, four-point-one, ezrin, radixin, moesin (FERM); Src homology 2 (SH2); pseudokinase; and kinase domains. The FERM and SH2 domains facilitate association with cytokine receptors and regulate the catalytic activity [7]. The pseudokinase domain, which interacts with the kinase domain, acts as a suppressor of the kinase domain’s catalytic activity and subsequently activates STAT1, 3, and 5 [8]. Until now, seven members of the STAT family (STATs 1–4, 5α, 5β, and 6) have been identified. Each of the STAT proteins shares highly conserved domains, including amino-terminal, coiled-coil, DNA binding, SH2, and transactivation domains [9]. The Asp170 residue in the helix α1 of the coiled-coil domain of STAT3 interacts with other transcription factors [10], and tyrosine phosphorylation of STAT3 by IL-6 is required for its receptor binding, dimerization, nuclear translocation, and DNA binding [11]. The SH2 domain is essential for STAT-cytokine receptor interactions as it recognizes the tyrosine residues in the cytokine receptors and forms stable homo- or heterodimers with other STAT proteins [12,13]. Cytokines induce the dimerization of STAT3 through the acetylation of Lys685 in the SH2 domain of STAT3, which is associated with the histone acetyltransferase p300 [14]. Besides, the N-terminal domain of STAT3 has multiple functions, including STAT3 tetramer stabilization, cooperative DNA binding, nuclear translocation, and protein–protein interactions [15] (Figure 1). [Figure: The contribution of signaling pathways that activate JAK/STAT3 signaling in cancer. Cytokines, growth factors, intracellular proteins, including non-receptor kinases (tyrosine or serine/threonine), can cooperate to induce the JAK/STAT3 signaling. (A) Various cytokines, peptide hormones, growth factors, and chemokines contribute to the activation of the JAK/STAT3 signaling to promote the progression of cancer. (B) The JAK/STAT3 signaling activated by tyrosine receptors and their cognate ligands, including neurotrophic receptors (TrkA, and TrkC), ILE/ILFR, PDGF-C/PDGFR, OSM/OSMR, CXCR12/CXCR7, HGF/c-MET, TGF-β/TGF receptors, IL-6/IL-6Rα/gp130, EGF/EGFR, Gastrin/GRPR, IGF/IGF1R, and Mk/Notch-1/2. Also, potential mechanisms by which tyrosine or serine/threonine kinases activate the JAK/STAT3 signaling through direct binding to JAK/STAT3 or indirect regulation of JAK/STAT3 activation. Once activated, phosphorylated and dimerized STAT3 enters the nucleus through importin-β1 and promotes the transcriptional expression of target genes to promote various cellular processes that are required for maintenance of survival in cancer.] 2. ROLE OF IL-6/JAK/STAT3 IN THE INDUCTION OF EMT STAT proteins are differentially implicated in cancer tumorigenesis. Although STAT1 is known to be involved in mediating the anti-tumor immunity and other STAT families are known to be involved in the promotion of cancer development, it is STAT3 that is most well studied as a significant intrinsic transcription factor in the induction of the EMT and in the pathogenesis of cancer (Figure 2) [16]. IL-6/JAK2/STAT3 activation enhances metastasis via induction of EMT by the upregulation of EMT-inducing transcription factors (EMT-TFs; Snail, Zeb1, JUNB, and Twist-1) and increases cell motility via focal adhesion kinase (FAK) activation [17,18,19,20]. In prostate cancer, paracrine IL-6/JAK2/STAT3 stimulates the autocrine IL-6 loop, and IGF-IR activation induced by both IL-6 and IGF enhances EMT through induction of the STAT3/NANOG/Slug axis [21,22]. [Figure: The contributions of intracellular signaling components to the inducing of EMT through activation of the JAK/STAT signaling. EMT program in cancer is associated with morphological and physiological changes of cancer, including the detachment of epithelial cells, enhanced invasiveness, tumor-initiating ability, and drug resistance. Enhanced EMT through upregulation of EMT-inducing transcription factors via the canonical and non-canonical JAK/STAT3 signaling leads to the downregulation of apoptotic signaling pathways, resistance to anticancer drugs and immunotherapy, induced cell proliferation, and CSC population.] STAT3 acts as a transcriptional activator through binding to the promoter of target genes in a tyrosine phosphorylation-dependent manner [23]. For instance, once activated, STAT3, in combination with estrogen receptor (ER), binds to the LIV-1 promoter leading to the induction of LIV-1 expression, followed by proteolytic N-terminal cleavage of the LIV-1 protein and its subsequent translocation to the plasma membrane. Subsequently, LIV-1 stabilizes Snail through inactivation of GSK3β [24,25,26]. In addition, RANKL is known to enhance EMT in prostate cancer through the STAT3/LIV-1 axis [27]. Moreover, IL-8-mediated production of IL-6 and TGF-β1 promotes binding of STAT3 to AUF-1 promoter, leading to the activation of breast stromal fibroblasts through the reduction of p16, p21, and p53 levels in a paracrine manner. In turn, elevated AUF-1 levels lead to enhanced EMT due to increased expression of SDF-1, α-SMA, TGF-β1, and IL-6 that results from binding of AUF1 to their respective promoters [28,29]. Furthermore, increased expression of Fra-1 [30] and PTTG1 [31] due to the binding of STAT3 to their promoters induce invasion and facilitates resistance to androgen deprivation therapy (AR). Additionally, induced RTVP-1 expression via binding of both C/EBPβ and STAT3 to the RTVP-1 promoter results in maintenance of the stemness property of glioblastoma cells and is associated with poor clinical outcomes in patients [32]. Besides, STAT3 induces UHRF1 expression via direct binding to its promoter. This is especially important in the context of cancer biology as the PHD and SRA domains of UHRF1 are involved in silencing the tumor suppressor genes in CRC cells [33]. The hallmarks of cancer coordinated by the STAT3-dependent transcriptional regulation of target proteins directly underpin the cellular responses. 3. CRITICAL MODULATORS OF THE